COG - Ticker AI Digest

Cambridge Cognition Holdings Plc 📰 2
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (COG) 2
COG 13:52
Cambridge Cognition Holdings Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
COG 11:05
Cambridge Cognition Holdings Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 1
COG 09:46
Cambridge Cognition Holdings Plc
£1.12m Placing & Subscription, TVR & PDMR Dealings
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 1
COG 06:01
Cambridge Cognition Holdings Plc
Launch of Speaker Identification Solution
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Cambridge Cognition Holdings plc has launched a **Speaker Identification Solution** to combat duplicate participant enrolment in clinical trials, a growing issue that compromises data integrity and study validity. Built on the companys AI-enabled voice technology platform, the solution uses advanced voice biometrics to verify participant identities across trial databases, achieving over 97% accuracy. It is GDPR and HIPAA compliant, scalable across languages, and applicable to various therapeutic areas. The product has already secured initial commercial deals, with deployment by a large pharmaceutical customer scheduled for Q4 2025. This launch strengthens Cambridge Cognitions suite of quality assurance tools, including its Automated Quality Assurance (AQUA) offering, and underscores its commitment to enhancing reliability and efficiency in clinical research. The solution addresses a critical under-recognised risk in clinical trials, with published data indicating up to 22% of participants may engage in overlapping trials. Rob Baker, Joint Managing Director and COO, highlighted the solutions potential to proactively mitigate risks and reinforce the companys leadership in voice analytics and data quality.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 1
COG 09:11
Cambridge Cognition Holdings Plc
Monument Therapeutics Partnership with FNIH
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Cambridge Cognition Holdings plc announced on August 19, 2025, that Monument Therapeutics, in which it holds a 20% stake, has partnered with the Foundation for the National Institutes of Health (FNIH) to conduct a clinical trial of MT1988, a novel treatment for cognitive impairment associated with schizophrenia. The trial is part of the FNIH-managed Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) program, a $44 million public-private initiative aimed at developing more effective treatments for schizophrenia. Cambridge Cognition’s digital cognitive assessment technologies played a key role in MT1988’s early development and biomarker strategy. The company retains a £1.8m equity stake and future royalty rights in Monument Therapeutics. This partnership marks a significant step in advancing precision treatments for brain health and underscores the value of Cambridge Cognition’s technology in addressing high unmet clinical needs.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
COG 06:01
Cambridge Cognition Holdings Plc
Interim Results
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 3
COG 13:52
Cambridge Cognition Holdings Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
COG 11:05
Cambridge Cognition Holdings Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
COG 16:22
Cambridge Cognition Holdings Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 9
COG 13:52
Cambridge Cognition Holdings Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
COG 11:05
Cambridge Cognition Holdings Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
COG 16:22
Cambridge Cognition Holdings Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
COG 09:59
Cambridge Cognition Holdings Plc
Investor Presentation via Investor Meet Company
COG 09:46
Cambridge Cognition Holdings Plc
£1.12m Placing & Subscription, TVR & PDMR Dealings
COG 06:02
Cambridge Cognition Holdings Plc
Changes to Board and Management
COG 06:01
Cambridge Cognition Holdings Plc
Interim Results
COG 09:11
Cambridge Cognition Holdings Plc
Monument Therapeutics Partnership with FNIH
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Cambridge Cognition Holdings plc announced on August 19, 2025, that Monument Therapeutics, in which it holds a 20% stake, has partnered with the Foundation for the National Institutes of Health (FNIH) to conduct a clinical trial of MT1988, a novel treatment for cognitive impairment associated with schizophrenia. The trial is part of the FNIH-managed Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) program, a $44 million public-private initiative aimed at developing more effective treatments for schizophrenia. Cambridge Cognition’s digital cognitive assessment technologies played a key role in MT1988’s early development and biomarker strategy. The company retains a £1.8m equity stake and future royalty rights in Monument Therapeutics. This partnership marks a significant step in advancing precision treatments for brain health and underscores the value of Cambridge Cognition’s technology in addressing high unmet clinical needs.
COG 06:01
Cambridge Cognition Holdings Plc
Launch of Speaker Identification Solution
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Cambridge Cognition Holdings plc has launched a **Speaker Identification Solution** to combat duplicate participant enrolment in clinical trials, a growing issue that compromises data integrity and study validity. Built on the companys AI-enabled voice technology platform, the solution uses advanced voice biometrics to verify participant identities across trial databases, achieving over 97% accuracy. It is GDPR and HIPAA compliant, scalable across languages, and applicable to various therapeutic areas. The product has already secured initial commercial deals, with deployment by a large pharmaceutical customer scheduled for Q4 2025. This launch strengthens Cambridge Cognitions suite of quality assurance tools, including its Automated Quality Assurance (AQUA) offering, and underscores its commitment to enhancing reliability and efficiency in clinical research. The solution addresses a critical under-recognised risk in clinical trials, with published data indicating up to 22% of participants may engage in overlapping trials. Rob Baker, Joint Managing Director and COO, highlighted the solutions potential to proactively mitigate risks and reinforce the companys leadership in voice analytics and data quality.

AI Crunch

Single-Ticker AI Crunch
COG signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Cambridge Cognition Holdings Plc. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full COG AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for COG on 2025-09-05.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
17225272
Enterprise Value
30613083
Public Float
54.9
Broker Target
56
Shares Out
46554785
Long Interest
100
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00B8DV9647
Market
LSE - AIM
Sector
Health Care Providers
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
-
Net Debt
613000.0
Cash
1295000.0
EPS
-0.04
Net Income
-1785000.0
Revenue
10342000.0
Enterprise Value
30613083
Trailing PE
-
Forward PE
12.837
Price Sales TTM
1.9025
Price Book MRQ
5.9865
EV Revenue
1.8791
EV EBITDA
100.234

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
26.6005
Institutions As Of
2025-09-26
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
2
Sale Director Dealing
0
Purchase TR1
4
Sale TR1
3
Broker Coverage Rows
0
Institution Holders Tracked
3
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

2 live catalysts just hit COG.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-09-05 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
2 Today
Catalyst Pulse
Cambridge Cognition Holdings Plc has fresh news flow feeding the chart narrative.
AI Charts Studio
COG Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-09-05 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast -3.53%
RSI Gauge
Price Change
AI Forecast